Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KYMR
- Price
- 45.87
- Stock movement down
- -0.57 (-1.23%)
- Company name
- Kymera Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.28B
- Ent value
- 3.31B
- Price/Sales
- 37.45
- Price/Book
- 3.67
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 44.15%
- 3 year return
- 46.93%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-08-27
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KYMR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 37.45 |
| Price to Book | 3.67 |
| EV to Sales | 37.81 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 71.50M |
| EPS (TTM) | -2.20 |
| FCF per share (TTM) | -1.95 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 87.56M |
| Gross profit (TTM) | 81.30M |
| Operating income (TTM) | -195.27M |
| Net income (TTM) | -167.47M |
| EPS (TTM) | -2.20 |
| EPS (1y forward) | -4.06 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 92.85% |
| Operating margin (TTM) | -223.00% |
| Profit margin (TTM) | -191.26% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 110.72M |
| Net receivables | 1.32M |
| Total current assets | 568.72M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 1.03B |
| Accounts payable | 6.49M |
| Short/Current long term debt | 88.23M |
| Total current liabilities | 66.53M |
| Total liabilities | 141.91M |
| Shareholder's equity | 892.93M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -124.67M |
| Capital expenditures (TTM) | 23.91M |
| Free cash flow (TTM) | -148.58M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -18.76% |
| Return on Assets | -16.18% |
| Return on Invested Capital | -18.23% |
| Cash Return on Invested Capital | -16.17% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 46.51 |
| Daily high | 46.66 |
| Daily low | 44.51 |
| Daily Volume | 948K |
| All-time high | 87.83 |
| 1y analyst estimate | 60.37 |
| Beta | 2.18 |
| EPS (TTM) | -2.20 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 29 Oct 2025 |
Downside potential
Loading...
Downside potential data
| KYMR | S&P500 | |
| Current price drop from All-time high | -47.77% | -3.04% |
| Highest price drop | -87.51% | -56.47% |
| Date of highest drop | 27 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -53.79% | -11.04% |
| Avg time to new high | 40 days | 12 days |
| Max time to new high | 1125 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.28B
Marketcap category
Mid-cap
Description
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Employees
218
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page